vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
Tecnoglass Inc. is the larger business by last-quarter revenue ($245.3M vs $139.2M, roughly 1.8× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 10.6%, a 24.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 2.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $11.4M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 12.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
ADMA vs TGLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $245.3M |
| Net Profit | $49.4M | $26.1M |
| Gross Margin | 63.8% | 40.0% |
| Operating Margin | 45.1% | 18.3% |
| Net Margin | 35.5% | 10.6% |
| Revenue YoY | 18.4% | 2.4% |
| Net Profit YoY | -55.9% | -44.5% |
| EPS (diluted) | $0.20 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $245.3M | ||
| Q3 25 | $134.2M | $260.5M | ||
| Q2 25 | $122.0M | $255.5M | ||
| Q1 25 | $114.8M | $222.3M | ||
| Q4 24 | $117.5M | $239.6M | ||
| Q3 24 | $119.8M | $238.3M | ||
| Q2 24 | $107.2M | $219.7M | ||
| Q1 24 | $81.9M | $192.6M |
| Q4 25 | $49.4M | $26.1M | ||
| Q3 25 | $36.4M | $47.2M | ||
| Q2 25 | $34.2M | $44.1M | ||
| Q1 25 | $26.9M | $42.2M | ||
| Q4 24 | $111.9M | $47.0M | ||
| Q3 24 | $35.9M | $49.5M | ||
| Q2 24 | $32.1M | $35.0M | ||
| Q1 24 | $17.8M | $29.7M |
| Q4 25 | 63.8% | 40.0% | ||
| Q3 25 | 56.3% | 42.7% | ||
| Q2 25 | 55.1% | 44.7% | ||
| Q1 25 | 53.2% | 43.9% | ||
| Q4 24 | 53.9% | 44.5% | ||
| Q3 24 | 49.8% | 45.8% | ||
| Q2 24 | 53.6% | 40.8% | ||
| Q1 24 | 47.8% | 38.8% |
| Q4 25 | 45.1% | 18.3% | ||
| Q3 25 | 38.0% | 25.1% | ||
| Q2 25 | 35.1% | 24.0% | ||
| Q1 25 | 30.4% | 26.7% | ||
| Q4 24 | 32.6% | 28.0% | ||
| Q3 24 | 33.1% | 28.4% | ||
| Q2 24 | 36.6% | 23.3% | ||
| Q1 24 | 26.7% | 21.3% |
| Q4 25 | 35.5% | 10.6% | ||
| Q3 25 | 27.1% | 18.1% | ||
| Q2 25 | 28.1% | 17.3% | ||
| Q1 25 | 23.4% | 19.0% | ||
| Q4 24 | 95.2% | 19.6% | ||
| Q3 24 | 30.0% | 20.8% | ||
| Q2 24 | 29.9% | 15.9% | ||
| Q1 24 | 21.7% | 15.4% |
| Q4 25 | $0.20 | $0.57 | ||
| Q3 25 | $0.15 | $1.01 | ||
| Q2 25 | $0.14 | $0.94 | ||
| Q1 25 | $0.11 | $0.90 | ||
| Q4 24 | $0.45 | $1.00 | ||
| Q3 24 | $0.15 | $1.05 | ||
| Q2 24 | $0.13 | $0.75 | ||
| Q1 24 | $0.08 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $104.1M |
| Total DebtLower is stronger | $72.1M | $174.4M |
| Stockholders' EquityBook value | $477.3M | $713.1M |
| Total Assets | $624.2M | $1.3B |
| Debt / EquityLower = less leverage | 0.15× | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $104.1M | ||
| Q3 25 | $61.4M | $127.1M | ||
| Q2 25 | $90.3M | $140.9M | ||
| Q1 25 | $71.6M | $160.2M | ||
| Q4 24 | $103.1M | $137.5M | ||
| Q3 24 | $86.7M | $124.8M | ||
| Q2 24 | $88.2M | $129.5M | ||
| Q1 24 | $45.3M | $138.8M |
| Q4 25 | $72.1M | $174.4M | ||
| Q3 25 | $72.4M | $114.7M | ||
| Q2 25 | — | $110.6M | ||
| Q1 25 | — | $110.6M | ||
| Q4 24 | $72.3M | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M | ||
| Q1 24 | — | $160.9M |
| Q4 25 | $477.3M | $713.1M | ||
| Q3 25 | $431.2M | $764.0M | ||
| Q2 25 | $398.3M | $736.0M | ||
| Q1 25 | $373.4M | $685.1M | ||
| Q4 24 | $349.0M | $631.2M | ||
| Q3 24 | $231.9M | $613.3M | ||
| Q2 24 | $188.3M | $574.8M | ||
| Q1 24 | $153.7M | $573.6M |
| Q4 25 | $624.2M | $1.3B | ||
| Q3 25 | $568.7M | $1.2B | ||
| Q2 25 | $558.4M | $1.2B | ||
| Q1 25 | $510.6M | $1.1B | ||
| Q4 24 | $488.7M | $1.0B | ||
| Q3 24 | $390.6M | $996.3M | ||
| Q2 24 | $376.4M | $942.5M | ||
| Q1 24 | $350.9M | $981.6M |
| Q4 25 | 0.15× | 0.24× | ||
| Q3 25 | 0.17× | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 0.21× | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× | ||
| Q1 24 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $31.0M |
| Free Cash FlowOCF − Capex | $34.6M | $11.4M |
| FCF MarginFCF / Revenue | 24.8% | 4.7% |
| Capex IntensityCapex / Revenue | 0.8% | 8.0% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $31.0M | ||
| Q3 25 | $13.3M | $40.0M | ||
| Q2 25 | $21.1M | $17.9M | ||
| Q1 25 | $-19.7M | $46.9M | ||
| Q4 24 | $50.2M | $61.1M | ||
| Q3 24 | $25.0M | $41.5M | ||
| Q2 24 | $45.6M | $34.5M | ||
| Q1 24 | $-2.2M | $33.4M |
| Q4 25 | $34.6M | $11.4M | ||
| Q3 25 | $-1.1M | $21.2M | ||
| Q2 25 | $18.7M | $-14.7M | ||
| Q1 25 | $-24.4M | $16.5M | ||
| Q4 24 | $47.5M | $35.4M | ||
| Q3 24 | $24.0M | $17.8M | ||
| Q2 24 | $43.6M | $14.2M | ||
| Q1 24 | $-4.6M | $23.6M |
| Q4 25 | 24.8% | 4.7% | ||
| Q3 25 | -0.8% | 8.2% | ||
| Q2 25 | 15.3% | -5.7% | ||
| Q1 25 | -21.2% | 7.4% | ||
| Q4 24 | 40.4% | 14.8% | ||
| Q3 24 | 20.0% | 7.5% | ||
| Q2 24 | 40.7% | 6.5% | ||
| Q1 24 | -5.6% | 12.2% |
| Q4 25 | 0.8% | 8.0% | ||
| Q3 25 | 10.7% | 7.2% | ||
| Q2 25 | 2.0% | 12.7% | ||
| Q1 25 | 4.1% | 13.7% | ||
| Q4 24 | 2.3% | 10.7% | ||
| Q3 24 | 0.9% | 9.9% | ||
| Q2 24 | 1.9% | 9.2% | ||
| Q1 24 | 2.9% | 5.1% |
| Q4 25 | 0.72× | 1.19× | ||
| Q3 25 | 0.36× | 0.85× | ||
| Q2 25 | 0.62× | 0.41× | ||
| Q1 25 | -0.73× | 1.11× | ||
| Q4 24 | 0.45× | 1.30× | ||
| Q3 24 | 0.70× | 0.84× | ||
| Q2 24 | 1.42× | 0.98× | ||
| Q1 24 | -0.12× | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
